Advertisement

Archives of Virology

, Volume 159, Issue 7, pp 1555–1565 | Cite as

NK cells in hepatitis B virus infection: a potent target for immunotherapy

  • Ziba Shabani
  • Masomeh Bagheri
  • Mohammad Zare-Bidaki
  • Gholamhossein Hassanshahi
  • Mohammad Kazemi Arababadi
  • Mozafar Mohammadi Nejad
  • Derek Kennedy
Brief Review

Abstract

Viruses, including hepatitis B virus (HBV), are the most prevalent and infectious agents that lead to liver disease in humans. Hepatocellular carcinoma (HCC) and cirrhosis of the liver are the most serious complications arising from prolonged forms of hepatitis B. Previous studies demonstrated that patients suffering from long-term HBV infections are unable to eradicate HBV from hepatocytes completely. The mechanisms responsible for progression of these forms of infection have not yet been clarified. However, it seems that there are differences in genetic and immunological parameters when comparing patients to subjects who successfully clear HBV infections, and these may represent the causes of long-term infection. Natural killer (NK) cells, the main innate immune cells that target viral infections, play important roles in the eradication of HBV from hepatocytes. NK cells carry several stimulatory and inhibitor receptors, and binding of receptors with their ligands results in activation and suppression of NK cells, respectively. The aim of this review is to address the recent information regarding NK cell phenotype, functions and modifications in hepatitis B. This review addresses the recent data regarding the roles of NK cells as novel targets for immunotherapies that target hepatitis B infection. It also discusses the potential to reduce the risk of HCC or cirrhosis of the liver by targeting NK cells.

Keywords

Natural Killer Cell Major Histocompatibility Complex Class Natural Killer Cell Function Natural Killer Cell Response CD56bright CD16 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This project was supported by a grant from the Rafsanjan University of Medical Sciences.

References

  1. 1.
    Afonina IS, Cullen SP, Martin SJ (2010) Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 235:105–116PubMedGoogle Scholar
  2. 2.
    Ahmadabadi BN, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D (2012) The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation 35(3):818–821. doi: 10.1007/s10753-011-9381-x PubMedCrossRefGoogle Scholar
  3. 3.
    Ahmadabadi BN, Hassanshahi G, Khoramdelazad H, Mirzaei V, Sajadi SM, Hajghani M, Khodadadi H, Pourali R, Arababadi MK, Kennedy D (2013) Downregulation of CCR5 expression on the peripheral blood CD8+ T cells of southeastern Iranian patients with chronic hepatitis B infection. Inflammation 36:136–140PubMedGoogle Scholar
  4. 4.
    Alison MR, Nicholson LJ, Lin WR (2011) Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 185:135–148PubMedCrossRefGoogle Scholar
  5. 5.
    Andrews DM, Andoniou CE, Scalzo AA, van Dommelen SL, Wallace ME, Smyth MJ, Degli-Esposti MA (2005) Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol 42:547–555PubMedCrossRefGoogle Scholar
  6. 6.
    Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G (2010) Decreased expression of CCR5 on the NK cells in occult HBV infected patients. Lab Med 41:735–738CrossRefGoogle Scholar
  7. 7.
    Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Miohit M, Hajghani M, Ahmadabadi BN, Kennedy D (2010) Evaluation of CCR5 expression on NK cells in Iranian patients with occult hepatitis B infection. Lab Med 41:735–738CrossRefGoogle Scholar
  8. 8.
    Arababadi MK, Pourfathollah AA, Jafarzadeh AA, Hassanshahi G (2010) Serum levels of Interleukin (IL)-10 and IL-17A in occult HBV infected south-east Iranian patients. Hepat Mon 10:31–35PubMedCentralPubMedGoogle Scholar
  9. 9.
    Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Daneshmandi S, Shamsizadeh A, Kennedy D (2011) Non-association of IL-12 +1188 and IFN-gamma +874 polymorphisms with cytokines serum level in occult HBV infected patients. Saudi J Gastroenterol 17:30–35PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Arababadi MK, Ahmadabadi BN, Kennedy D (2012) Current information on the immunological status of occult hepatitis B infection. Transfusion 52:1819–1826PubMedCrossRefGoogle Scholar
  11. 11.
    Attallah AM, Tabll AA, El-Sadany M, Ibrahim TA, El-Dosoky I (2003) Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma. Clin Exp Med 3:181–185PubMedCrossRefGoogle Scholar
  12. 12.
    Barreira da Silva R, Munz C (2011) Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals. Cell Mol Life Sci 68:3505–3518PubMedCrossRefGoogle Scholar
  13. 13.
    Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286–2294PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Bernardini G, Gismondi A, Santoni A (2012) Chemokines and NK cells: regulators of development, trafficking and functions. Immunol Lett 145:39–46PubMedCrossRefGoogle Scholar
  15. 15.
    Biber JL, Jabbour S, Parihar R, Dierksheide J, Hu Y, Baumann H, Bouchard P, Caligiuri MA, Carson W (2002) Administration of two macrophage-derived interferon-gamma-inducing factors (IL-12 and IL-15) induces a lethal systemic inflammatory response in mice that is dependent on natural killer cells but does not require interferon-gamma. Cell Immunol 216:31–42PubMedCrossRefGoogle Scholar
  16. 16.
    Bocko D, Kosmaczewska A, Ciszak L, Teodorowska R, Frydecka I (2002) CD28 costimulatory molecule—expression, structure and function. Arch Immunol Ther Exp (Warsz) 50:169–177Google Scholar
  17. 17.
    Böhm W, Schirmbeck R, Elbe A, Melber K, Diminky D, Kraal G, van Rooijen N, Barenholz Y, Reimann J (1995) Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol 155:3313–3321PubMedGoogle Scholar
  18. 18.
    Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, Dariz A, Guillermet C, Pernollet M, Zarski JP, Marche PN, Leroy V, Jouvin-Marche E (2009) Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 51:458–467PubMedCrossRefGoogle Scholar
  19. 19.
    Braunschweig A, Poehlmann TG, Busch S, Schleussner E, Markert UR (2011) Signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling (SOCS3) balance controls cytotoxicity and IL-10 expression in decidual-like natural killer cell line NK-92. Am J Reprod Immunol 66:329–335PubMedCrossRefGoogle Scholar
  20. 20.
    Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, Wood SM (2011) Molecular mechanisms of natural killer cell activation. J Innate Immun 3:216–226PubMedCrossRefGoogle Scholar
  21. 21.
    Caligiuri MA (2008) Human natural killer cells. Blood 112:461–469PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Cao D, Xu H, Guo G, Ruan Z, Fei L, Xie Z, Wu Y, Chen Y (2013) Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. Inflammation 36(1):110–120Google Scholar
  23. 23.
    Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M (2000) A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 32:317–324PubMedCrossRefGoogle Scholar
  24. 24.
    Chen Y, Cheng M, Tian Z (2006) Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol 3:373–378PubMedGoogle Scholar
  25. 25.
    Cheng Q, Li N, Chen M, Zheng J, Qian Z, Wang X, Huang C, Li Q, Lin Q, Shi G (2013) Fuzheng Huayu inhibits carbon tetrachloride-induced liver fibrosis in mice through activating hepatic NK cells. J Ethnopharmacol 145:175–181PubMedCrossRefGoogle Scholar
  26. 26.
    Chisari FV, Isogawa M, Wieland SF (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58:258–266CrossRefGoogle Scholar
  27. 27.
    Cobleigh MA, Robek MD (2013) Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis. Am J Pathol 182:21–28PubMedCrossRefGoogle Scholar
  28. 28.
    de la Fuente RA, Gutierrez ML, Garcia-Samaniego J, Fernandez-Rodriguez C, Lledo JL, Castellano G (2011) Pathogenesis of occult chronic hepatitis B virus infection. World J Gastroenterol 17:1543–1548PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA (2003) Biology and clinical impact of human natural killer cells. Int J Hematol 78:7–17PubMedCrossRefGoogle Scholar
  30. 30.
    Gao B, Radaeva S, Jeong WI (2007) Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 1:173–180PubMedCrossRefGoogle Scholar
  31. 31.
    Garstka MA, Neefjes J (2013) How to target MHC class II into the MIIC compartment. Mol Immunol 55:162–165PubMedCrossRefGoogle Scholar
  32. 32.
    Glassner A, Eisenhardt M, Kramer B, Korner C, Coenen M, Sauerbruch T, Spengler U, Nattermann J (2012) NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest 92:967–977PubMedCrossRefGoogle Scholar
  33. 33.
    Gunturi A, Berg RE, Forman J (2004) The role of CD94/NKG2 in innate and adaptive immunity. Immunol Res 30:29–34PubMedCrossRefGoogle Scholar
  34. 34.
    Hellerbrand C (2013) Hepatic stellate cells-the pericytes in the liver. Pflugers Arch 465(6):775–778Google Scholar
  35. 35.
    Hulikova K, Benson V, Svoboda J, Sima P, Fiserova A (2009) N-Acetyl-d-glucosamine-coated polyamidoamine dendrimer modulates antibody formation via natural killer cell activation. Int Immunopharmacol 9:792–799PubMedCrossRefGoogle Scholar
  36. 36.
    Inngjerdingen M, Kveberg L, Naper C, Vaage JT (2011) Natural killer cell subsets in man and rodents. Tissue Antigens 78:81–88PubMedCrossRefGoogle Scholar
  37. 37.
    Ishimaru H, Matsuda T, Hara T (1989) Circulating mature NK (Leu11+) cells positive for IL2 receptor and HLA-DR in patients with various liver diseases and asymptomatic HBsAg carriers. Nihon Shokakibyo Gakkai Zasshi 86:2721–2727PubMedGoogle Scholar
  38. 38.
    Jinushi M, Takehara T, Tatsumi T, Yamaguchi S, Sakamori R, Hiramatsu N, Kanto T, Ohkawa K, Hayashi N (2007) Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4+ CD25+ T cells with PD-1-dependent regulatory activities. Immunology 120:73–82PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Jobim M, Jobim LF (2008) Natural killer cells and immune surveillance. J Pediatr (Rio J) 84:S58–S67CrossRefGoogle Scholar
  40. 40.
    Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, Liang X, Gao L, Ma C (2010) T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol 52:322–329PubMedCrossRefGoogle Scholar
  41. 41.
    Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921–930PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Kanchan V, Panda AK (2007) Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28:5344–5357PubMedCrossRefGoogle Scholar
  43. 43.
    Kennedy M, Alexopoulos SP (2010) Hepatitis B virus infection and liver transplantation. Curr Opin Organ Transplant 15:310–315PubMedCrossRefGoogle Scholar
  44. 44.
    Khorramdelazad H, Hassanshahi G, Ahmadabadi BN, Arababadi MK (2012) High serum levels of TGF-β in Iranians with chronic HBV infection. Hepat Mon 12:e7581PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Krzewski K, Coligan JE (2012) Human NK cell lytic granules and regulation of their exocytosis. Front Immunol 3:335PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Lee CS, Lee FZ (1989) Natural killer cell activity in hepatocellular carcinoma patients. Taiwan Yi Xue Hui Za Zhi 88:478–482PubMedGoogle Scholar
  47. 47.
    Lee CS (1991) Lymphocytes and their subsets in the peripheral blood of hepatocellular carcinoma patients. J Formos Med Assoc 90:626–630PubMedGoogle Scholar
  48. 48.
    Lee J, Chae D, Kim S, Nam E, Jang M, Lee J, Kim H, Yoo J (2004) Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat 11:130–135PubMedCrossRefGoogle Scholar
  49. 49.
    Li F, Wei H, Gao Y, Xu L, Yin W, Sun R, Tian Z (2013) Blocking the natural killer (NK) cell inhibitory receptor NKG2A increases activity of human NK cells and clears HBV infection in mice. Gastroenterology 144(2):392–401Google Scholar
  50. 50.
    Li J, Han Y, Jin K, Wan Y, Wang S, Liu B, Liu Y, Lu S, Huang Z (2011) Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection. Virol J 8:199PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Li M, Yao Y, Gao YQ (2010) Expression profile of immune effector molecules in natural killer cells in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 18:96–100PubMedGoogle Scholar
  52. 52.
    Lu Z, Zhang B, Chen S, Gai Z, Feng Z, Liu X, Liu Y, Wen X, Li L, Jiao Y, Ma C, Shao S, Cui X, Chen G, Li J, Zhao Y (2008) Association of KIR genotypes and haplotypes with susceptibility to chronic hepatitis B virus infection in Chinese Han population. Cell Mol Immunol 5:457–463PubMedCrossRefGoogle Scholar
  53. 53.
    Ma J, Guo X, Wu X, Li J, Zhu X, Li Z, Pan L, Li T, Li H, Liu Y (2010) Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population. J Med Virol 82:1501–1507PubMedCrossRefGoogle Scholar
  54. 54.
    Martin-Fontecha A, Lord GM, Brady HJ (2011) Transcriptional control of natural killer cell differentiation and function. Cell Mol Life Sci 68:3495–3503PubMedCrossRefGoogle Scholar
  55. 55.
    Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, Leroy V, Plumas J, Aspord C (2012) Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143(6):1586–1596Google Scholar
  56. 56.
    Mohammadi Nejad M, Salehi E, Mesdaghi M, Atarod L, Movahedi M, Gheflati Z, Aboufazeli T, Vodjgani M (2013) Increased expression of CD69 antigen on human peripheral blood natural killer cells in patients with allergic rhinitis. Iran J Allergy Asthma Immunol 12:68–74PubMedGoogle Scholar
  57. 57.
    Nakamura T, Morizane T, Watanabe T, Tsuchimoto K, Inagaki Y, Kumagai N, Tsuchiya M (1983) Decreased natural killer activity in patients with liver cirrhosis. Int J Cancer 32:573–575PubMedCrossRefGoogle Scholar
  58. 58.
    Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H, Chayama K (2012) Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology 56:555–566PubMedCrossRefGoogle Scholar
  59. 59.
    Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, Mondelli MU (2009) Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137:1151–1160 (pp 1160 e1151–1157)PubMedCrossRefGoogle Scholar
  60. 60.
    Papatheodoridis GV (2013) Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues? Liver Int 33(Suppl 1):151–156PubMedCrossRefGoogle Scholar
  61. 61.
    Park GH, Kim KY, Cheong JY, Cho SW, Kwack K (2012) Association of GNLY genetic polymorphisms with chronic liver disease in a Korean population. DNA Cell Biol 31:1492–1498PubMedCentralPubMedCrossRefGoogle Scholar
  62. 62.
    Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK (2010) Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6:e1001227PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Pinzani M, Macias-Barragan J (2010) Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol 4:459–472PubMedCrossRefGoogle Scholar
  64. 64.
    Poggi A, Prevosto C, Zancolli M, Canevali P, Musso A, Zocchi MR (2007) NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann N Y Acad Sci 1109:47–57PubMedCrossRefGoogle Scholar
  65. 65.
    Ratnam DT, Sievert W, Visvanathan K (2012) Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B. Cell Immunol 279:109–115PubMedCrossRefGoogle Scholar
  66. 66.
    Rehermann B (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19:859–868PubMedCrossRefGoogle Scholar
  67. 67.
    Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV (2005) Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 42:1028–1036PubMedCrossRefGoogle Scholar
  68. 68.
    Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA (2012) Cytokine activation induces human memory-like NK cells. Blood 120:4751–4760PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Rousalova I, Krepela E (2010) Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 37:1361–1378PubMedGoogle Scholar
  70. 70.
    Scaglione SJ, Lok AS (2012) Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142(1360–1368):e1361Google Scholar
  71. 71.
    Seijkens T, Engel D, Tjwa M, Lutgens E (2010) The role of CD154 in haematopoietic development. Thromb Haemost 104:693–701PubMedCrossRefGoogle Scholar
  72. 72.
    Shi CC, Tjwa ET, Biesta PJ, Boonstra A, Xie Q, Janssen HL, Woltman AM (2012) Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells. J Viral Hepat 19:e26–e33PubMedCrossRefGoogle Scholar
  73. 73.
    Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG (2002) Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci 99:13717–13722PubMedCentralPubMedCrossRefGoogle Scholar
  74. 74.
    Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H (2012) TGF-beta1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 8:e1002594PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Szabo G, Dolganiuc A (2008) The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity. Crit Rev Immunol 28:61–94PubMedCrossRefGoogle Scholar
  76. 76.
    Tang H, Li C, Wang L, Zhang H, Fan Z (2012) Granzyme H of cytotoxic lymphocytes is required for clearance of the hepatitis B virus through cleavage of the hepatitis B virus X protein. J Immunol 188:824–831PubMedCrossRefGoogle Scholar
  77. 77.
    Tang Q, Ahn YO, Southern P, Blazar BR, Miller JS, Verneris MR (2011) Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. Blood 117:4052–4055PubMedCentralPubMedCrossRefGoogle Scholar
  78. 78.
    Tang ST, Wang M, Lamberth K, Harndahl M, Dziegiel M, Claesson M, Buus S, Lund O (2008) MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination. Arch Virol 153:1833–1844PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Tefanova VT, Priimiagi LS, Tallo TG (2001) Functional and metabolic activity of peripheral blood neutrophils in acute viral hepatitis B and C. Zh Mikrobiol Epidemiol Immunobiol 43–47Google Scholar
  80. 80.
    Terrazzano G, Pisanti S, Grimaldi S, Sica M, Fontana S, Carbone E, Zappacosta S, Ruggiero G (2004) Interaction between natural killer and dendritic cells: the role of CD40, CD80 and major histocompatibility complex class i molecules in cytotoxicity induction and interferon-gamma production. Scand J Immunol 59(4):356–362PubMedCrossRefGoogle Scholar
  81. 81.
    Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM (2011) Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol 54:209–218PubMedCrossRefGoogle Scholar
  82. 82.
    Tjwa ET, van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM (2012) Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 86:4102–4109PubMedCentralPubMedCrossRefGoogle Scholar
  83. 83.
    Tujios SR, Lee WM (2013) Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 29:250–256PubMedCrossRefGoogle Scholar
  84. 84.
    Vargas CL, Poursine-Laurent J, Yang L, Yokoyama WM (2011) Development of thymic NK cells from double negative 1 thymocyte precursors. Blood 118:3570–3578PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, Chemin I (2011) Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 6:e26315PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Wang S, Xia P, Shi L, Fan Z (2012) FADD cleavage by NK cell granzyme M enhances its self-association to facilitate procaspase-8 recruitment for auto-processing leading to caspase cascade. Cell Death Differ 19:605–615PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, Luce J, Metes D (2012) Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 42:541–550PubMedCentralPubMedCrossRefGoogle Scholar
  88. 88.
    Xibing G, Xiaojuan Y, Juanhua W, Zhong H (2013) Relationship between HBV genotypes B, C and follicular helper T cells in patients with chronic hepatitis B and its significance. Hepat Mon 13:e6221PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.
    Yamagiwa S, Kamimura H, Ichida T (2009) Natural killer cell receptors and their ligands in liver diseases. Med Mol Morphol 42:1–8PubMedCrossRefGoogle Scholar
  90. 90.
    Yin W, Xu L, Sun R, Wei H, Tian Z (2012) Interleukin-15 suppresses hepatitis B virus replication via IFN-beta production in a C57BL/6 mouse model. Liver Int 32:1306–1314PubMedCrossRefGoogle Scholar
  91. 91.
    Yoshida O, Akbar F, Miyake T, Abe M, Matsuura B, Hiasa Y, Onji M (2008) Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell. Clin Exp Immunol 152:174–181PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Zeng XH, Sha WH, Li YY, Nie YQ, Li QN, Liang PZ (2009) Expression of NK cells receptor NKG2D from peripheral blood in patients with primary hepatic carcinoma and its clinical significance. Zhonghua Yi Xue Za Zhi 89:1272–1274PubMedGoogle Scholar
  93. 93.
    Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z (2009) Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58:1275–1285PubMedCrossRefGoogle Scholar
  94. 94.
    Zhao J, Li Y, Jin L, Zhang S, Fan R, Sun Y, Zhou C, Shang Q, Li W, Zhang Z, Wang FS (2012) Natural killer cells are characterized by the concomitantly increased interferon-gamma and cytotoxicity in acute resolved hepatitis B patients. PLoS One 7:e49135PubMedCentralPubMedCrossRefGoogle Scholar
  95. 95.
    Zhi-ming L, Yu-lian J, Zhao-lei F, Chun-xiao W, Zhen-fang D, Bing-chang Z, Yue-ran Z (2007) Polymorphisms of killer cell immunoglobulin-like receptor gene: possible association with susceptibility to or clearance of hepatitis B virus infection in Chinese Han population. Croat Med J 48:800–806PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Zhu J, Huang X, Yang Y (2010) NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus. J Immunol 185:7480–7486PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Zhu R, Mancini-Bourgine M, Zhang XM, Bayard F, Deng Q, Michel ML (2011) Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice. J Virol 85:10201–10212PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Ziba Shabani
    • 1
  • Masomeh Bagheri
    • 1
  • Mohammad Zare-Bidaki
    • 1
  • Gholamhossein Hassanshahi
    • 2
  • Mohammad Kazemi Arababadi
    • 1
  • Mozafar Mohammadi Nejad
    • 4
  • Derek Kennedy
    • 3
  1. 1.Immunology of Infectious Diseases Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  2. 2.Molecular Medicine Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  3. 3.School of Biomolecular and Physical Science, Eskitis Institute for Drug DiscoveryGriffith UniversityNathanAustralia
  4. 4.Razi Herbal Medicine Research CenterLorestan University of Medical SciencesKhorramabadIran

Personalised recommendations